Clinical significance of uremic toxin indoxyl sulfate and inflammation in the development of vascular calcification and cardiovascular complications in stage C3-C5D chronic kidney disease

被引:1
|
作者
Dzgoeva, Fatima U. [1 ]
Remizov, Oleg, V [1 ]
Goloeva, Victoria G. [1 ]
Ikoeva, Zarina R. [1 ]
机构
[1] North Ossetian State Med Acad, Vladikavkaz, Russia
关键词
chronic kidney disease; indoxyl sulfate; interleukin-6; tumor necrosis factor-& alpha; calcification of the heart and aorta;
D O I
10.26442/00403660.2023.06.202267
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim. To clarify the role of the uremic toxin indoxyl sulfate (IS) and inflammation in the development of vascular calcification and cardiovascular complications in chronic kidney disease (CKD).Materials and methods. One hundred fifteen patients aged 25 to 68 years with CKD stage C3-C5D were examined. Serum concentrations of IS, interleukin 6 (IL-6), tumor necrosis factor (TNF-a), troponin I, parathyroid hormone were determined by enzyme immunoassay using kits from BluGene biotech (Shanghai, China), Cloud-Clone Corp. (USA), ELISA Kit (Biomedica, Austria).Results. An increase in the serum concentration of IS, IL-6, TNF-a was revealed, which was significantly associated with a deterioration in renal function and changes in the morphological and functional parameters of the heart and aorta.Conclusion. High concentrations of IS, IL-6, TNF-a, which are closely associated with an increase in renal failure and cardiovascular complications, indicate their significant role in vascular calcification, which underlies the damage to the cardiovascular system in CKD.
引用
收藏
页码:468 / 474
页数:7
相关论文
共 30 条
  • [21] Clinical factors for predicting cardiovascular risk, need for renal replacement therapy, and mortality in patients with non–dialysis-dependent stage 3–5 chronic kidney disease from the Salford Kidney Study
    Ana Filipa Alexandre
    Matthias Stoelzel
    Amit Kiran
    Alberto Garcia-Hernandez
    Antonia Morga
    Philip A. Kalra
    Journal of Nephrology, 2023, 36 : 1639 - 1649
  • [22] Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: Final results of the C-SURFER phase 3 study
    Barr, E.
    Roth, D.
    Bruchfeld, A.
    Martin, P.
    Nelson, D. R.
    Silva, M.
    Monsour, H.
    Alric, L.
    Wan, S.
    Jackson, B.
    Nguyen, B. Y.
    Wahl, J.
    Greaves, W.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 65 - 66
  • [23] The role of exercise training on cardiovascular risk factors and heart disease in patients with chronic kidney disease G3-G5 and G5D: a Clinical Consensus Statement of the European Association of Preventive Cardiology of the ESC and the European Association of Rehabilitation in Chronic Kidney Disease
    Kouidi, Evangelia
    Hanssen, Henner
    Anding-Rost, Kirsten
    Cupisti, Adamasco
    Deligiannis, Asterios
    Grupp, Clemens
    Koufaki, Pelagia
    Leeson, Paul
    Segura-Orti, Eva
    Van Craenenbroeck, Amaryllis
    Van Craenenbroeck, Emeline
    Clyne, Naomi
    Halle, Martin
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 31 (12) : 1493 - 1515
  • [24] Clinical factors for predicting cardiovascular risk, need for renal replacement therapy, and mortality in patients with non-dialysis-dependent stage 3-5 chronic kidney disease from the Salford Kidney Study
    Alexandre, Ana Filipa
    Stoelzel, Matthias
    Kiran, Amit
    Garcia-Hernandez, Alberto
    Morga, Antonia
    Kalra, Philip A. A.
    JOURNAL OF NEPHROLOGY, 2023, 36 (06) : 1639 - 1649
  • [25] The Association between 25-Hydroxyvitamin D and Hemoglobin A1c Levels in Patients with Type 2 Diabetes and Stage 1-5 Chronic Kidney Disease
    Kajbaf, Farshad
    Mentaverri, Romuald
    Diouf, Momar
    Fournier, Albert
    Kamel, Said
    Lalau, Jean-Daniel
    INTERNATIONAL JOURNAL OF ENDOCRINOLOGY, 2014, 2014
  • [26] Elbasvir/Grazoprevir (EBR/GZR) treatment of Hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study
    Bruchfeld, Annette
    Roth, David
    Martin, Paul
    Nelson, David
    Stanislas, Pol
    Carlota Londono, Maria
    Viviani, Daniele
    Wan, Shyan
    Arduino, Jeanmarie
    Robertson, Michael
    Nguyen, Bachyen
    Wahl, Janice
    Barr, Eliav
    Greaves, Wayne
    SWISS MEDICAL WEEKLY, 2016, 146 : 23S - 23S
  • [27] Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
    Roth, David
    Nelson, David R.
    Bruchfeld, Annette
    Liapakis, AnnMarie
    Silva, Marcelo
    Monsour, Howard, Jr.
    Martin, Paul
    Pol, Stanislas
    Londono, Maria-Carlota
    Hassanein, Tarek
    Zamor, Philippe J.
    Zuckerman, Eli
    Wan, Shuyan
    Jackson, Beth
    Nguyen, Bach-Yen
    Robertson, Michael
    Barr, Eliav
    Wahl, Janice
    Greaves, Wayne
    LANCET, 2015, 386 (10003): : 1537 - 1545
  • [28] Association of serum 25-hydroxyvitamin D3, fibroblast growth factor-23, and C1q/tumor necrosis factor-related protein-3 with coronary artery calcification in nondialysis chronic kidney disease patients
    Zhu, Yuanjie
    Hu, Zhijuan
    Liu, Yu
    Qin, Congcong
    Chen, Xing
    Shi, Yanan
    Wang, Lijun
    RENAL FAILURE, 2023, 45 (01)
  • [29] Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study (vol 386, pg 1537, 2015)
    Roth, D.
    Nelson, D. R.
    Bruchfeld, A.
    LANCET, 2015, 386 (10006): : 1824 - 1824
  • [30] Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
    Bruchfeld, Annette
    Roth, David
    Martin, Paul
    Nelson, David R.
    Pol, Stanislas
    Londono, Maria-Carlota
    Monsour, Howard, Jr.
    Silva, Marcelo
    Hwang, Peggy
    Arduino, Jean-Marie
    Robertson, Michael
    Bach-Yen Nguyen
    Wahl, Janice
    Barr, Eliav
    Greaves, Wayne
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (08): : 585 - 594